Nabiximols, an oromucosal spray of a complete cannabis plant extract having a one:1 ratio of THC to cannabidiol (CBD), was at first licensed and authorised in Europe, the uk, and copyright for the procedure of suffering and spasticity affiliated with many sclerosis (GW Prescribed drugs, 2016; Pertwee,